Bisphosphonates for osteoporosis in postmenopausal women
Bisphosphonates for osteoporosis in postmenopausal women
Cochrane Review
8 SoF Entries
Summary of Findings
Key results and quality assessments using GRADE methodology
| Outcome | Effect | Participants | Studies | Certainty |
|---|---|---|---|---|
|
Presence of dry socket
Placebo/no treatment |
0.38 | - | - | Not assessed |
|
Adverse events
Placebo/no treatment |
nan | - | - | Not assessed |
|
Healing
Alvogyl |
nan | - | - | Not assessed |
|
Pain
Alvogyl |
nan | - | - | Not assessed |
|
Swelling
Alvogyl |
nan | - | - | Not assessed |
|
Limitation of chewing or swallowing
Alvogyl |
nan | - | - | Not assessed |
|
Fever
Alvogyl |
nan | - | - | Not assessed |
|
Adverse effects
Alvogyl |
nan | - | - | Not assessed |
GRADE Certainty of Evidence:
High
Very confident in the effect estimate
Moderate
Moderately confident in the effect estimate
Low
Limited confidence in the effect estimate
Very Low
Very little confidence in the effect estimate
Review Information
| Review ID: | CD006968 |
| Outcomes: | 8 assessed |
Related Content
Evidence Quality Distribution:
Not assessed:
8